Newnham et al. BMC Cancer 2011, 11:93 http://www.biomedcentral.com/1471-2407/11/93 advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-51, 21. 36. Takahashi T, et al: p53: a frequent target for genetic abnormalities in lung cancer. Science 1989, 246:491-4, 4929. 37. Sekido Y, Fong K, Minna J: Molecular biology of lung cancer. [book auth.] V DeVita, S Hellman and S Rosenberg. In Cancer - principles and practice of oncology. s.l. Volume 1. Lippincott Williams & Wilkins; 2001:917-25. 38. Pao W, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PloS Med 2005, 2:c73, 3. 39. Peeters M, et al: Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009, 115:1544-54, 7. 40. Bokemeyer C, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-71, 5. 41. Amado RG, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-34, 10. 42. Schmid RS, et al: NCAM stimulates the Ras-MAPK pathway and CREB phosphorylation in neuronal cells. J Neurobiol 1999, 38:542-58, 4. 43. Son H, et al: Reciprocal actions of NCAM and tPA via a Ras-dependent MAPK activation in rat hippocampal neurons. Biochem Biophys Res Commun 2002, 298:262-8, 2. 44. Ramaswamy S, et al: A molecular signature of metastasis in primary solid tumours. Nature Genetics 2003, 33:49-54. 45. Weigelt B, et al: Gene expression profiles of primary breast tumours maintained in distant metastases. Proc Nat Acad Sciences USA 2003, 100:15901-05, 26. 46. Akervall J, et al: The gene ratios c-MYC:cyclin-dependent kinase (CDK) N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res 2003, 9:1750-5, 5. 47. Hu Y, et al: Identification and functional characterization of a novel human Misshapen/Nck interacting kinase-related kinase, hMINK-beta. J Biol Chem 2004, 54387-54397. 48. Oh J, et al: The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107:789-800. 49. Chang HC, Cho CY, Hung WC: Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Sci 2007, 98:169-73, 2. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/11/93/prepub doi:10.1186/1471-2407-11-93 Cite this article as: Newnham et al.: Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer 2011 11:93. Page 11 of 11 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit